Advertisement
UK markets closed
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     
  • AIM

    755.28
    +2.16 (+0.29%)
     
  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     
  • GBP/USD

    1.2494
    -0.0017 (-0.13%)
     
  • Bitcoin GBP

    50,418.50
    -1,264.46 (-2.45%)
     
  • CMC Crypto 200

    1,304.48
    -92.06 (-6.59%)
     
  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     
  • DOW

    38,239.66
    +153.86 (+0.40%)
     
  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     
  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

BUZZ-Top of the Street: Chr Hansen, ASML, Adecco, Intertek

A round-up of notable broker activity this morning from Europe's top-ranked* analysts:

** Goldman Sachs cuts Intertek to "sell" from "neutral", forecasting a slowdown in EBITA margin expansion over 2019-23 period

** GS also downgrades Adecco to "sell" from "buy", sees negative organic growth for two consecutive quarters

** Berenberg cuts Chr Hansen to "sell" from "hold" after Q4 decline and a low organic growth forecast of 7%

** Berenberg downgrades Just Eat to "hold" from "buy", citing tough market competition, delivery costs and its 2020 EBITDA estimate being 10% below consensus

ADVERTISEMENT

** Kepler Cheuvreux notes improved LafargeHolcim balance sheet and increasing EBITDA margin, upgrades to "buy" from "hold"

** Citi upgrades Babcock to "neutral" from "sell", says shares already capture its 7-9% margin range

INITIATIONS AND REINSTATEMENTS

** Societe Generale expects ASML's gross and EBIT margins to rise on the back of the semiconductor industry's next spending wave, initiates with "buy"

(*Analyst rankings from Thomson Reuters StarMine. Scale is from 1-star to 5-star with 5 being best. Analysts ranked on earnings accuracy as well as relative performance of recommendations over trailing 12-month & 24-month periods.)